摘要
心力衰竭是心脏科最后的“战场”,根据左室射血分数的不同,目前将慢性心力衰竭分为3类,其中射血分数保留型心力衰竭(HFpEF)病理生理机制复杂,预后差,治疗策略有限。近期研究表明,钠-葡萄糖协同转运蛋白2抑制剂、血管紧张素受体脑啡肽酶抑制剂、吡非尼酮、抗炎药物、可溶性鸟苷酸环化酶激动剂、静脉补铁治疗、多肽类等用于HFpEF的治疗研究取得部分进展,该文就此进行综述。
Heart failure(HF)is the final"battlefield"in cardiology,currently,based on the measurement of left ventricular ejection fraction it has been divided into three distinct phenotypes.Among that,heart failure with preserved ejection fraction(HFpEF)has complex pathophysiological mechanisms and poor prognosis,and the treatment strategy is limited.Recent studies have shown some progress in pharmacological therapy for HFpEF,such as sodium-dependent glucose transporters 2 inhibitors(SGLT-2),angiotensin receptor–neprilysin inhibitor,pirfenidone,anti-inflammatory drugs,soluble guanylate cyclase agonists,intravenous iron supplementation therapy,and peptide drugs.In this article,the advanced in pharmacological treatments for HFpEF have been reviewed.
作者
崔小娇
谢波
易小清
陈祝君
雷洋
黄雪飞
边原
CUI Xiaojiao;XIE Bo;YI Xiaoqing;CHEN Zhujun;LEI Yang;HUANG Xuefei;BIAN Yuan(Department of Pharmacy&Personalized Drug Therapy Key Laboratory of Sichuan Province,Sichuan Provincial People's Hospital/Affiliated Hospital of University of Electronic Science and Technology of China,Sichuan Academy of Medical Sciences,Chengdu 610072,China;Division of Cardiology,Chengdu Integrated TCM&Western Medicine Hospital,Chengdu First People's Hospital,Chengdu 610000,China)
出处
《医药导报》
CAS
北大核心
2023年第2期212-216,共5页
Herald of Medicine
基金
国家重点研发计划(2020YFC2005500)
四川省科技厅重点研发计划(2019YFS0514)
四川省干部保健科研课题(川干研2021-226)
四川省医学会静脉血栓栓塞症防治专项科研课题(2019HR02)
四川省人民医院院级科研基金临床研究及转化项目(2018LY09)。
